ADIM
RXST icon

Alpha DNA Investment Management’s RxSight RXST Stock Holding History

Alpha DNA Investment Management’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,752
Closed -$473K – 148
2024
Q4 		$473K Buy
+13,752
New +$620K 0.18% 117
2024
Q3 		– Sell
-7,340
Closed -$442K – 249
2024
Q2 		$442K Sell
7,340
-4,442
-38% -$254K 0.17% 137
2024
Q1 		$608K Sell
11,782
-1,383
-11% -$67.9K 0.22% 99
2023
Q4 		$531K Sell
13,165
-7,714
-37% -$226K 0.21% 111
2023
Q3 		$582K Buy
+20,879
New +$623K 0.24% 93

Other funds holding RXST

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

Alpha DNA Investment Management's RXST Position: Q1 2025 in Review

Alpha DNA Investment Management sold out of RxSight (RXST) in Q1 2025, closing a stake of 13,752 shares — an estimated $473K sold.

Alpha DNA Investment Management first reported a position in RXST in Q3 2023 and held it in 5 quarters. The position peaked at $608K in Q1 2024. 192 funds tracked by Wall St. Rank hold RXST as of Q1 2025.

  • Alpha DNA Investment Management reported no remaining RxSight position as of Q1 2025 after selling out during the quarter.
  • Alpha DNA Investment Management sold 13,752 RxSight shares in Q1 2025, an estimated $473K.
  • Alpha DNA Investment Management first reported a position in RxSight in Q3 2023 and held it in 5 quarters.
  • Alpha DNA Investment Management's RxSight position peaked at $608K in Q1 2024.
  • 192 funds tracked by Wall St. Rank held RxSight as of Q1 2025.

Based on Alpha DNA Investment Management's 13F filing for Q1 2025, filed 19 May 2025.